Results 21 to 30 of about 501,389 (308)

The interleukin-2 receptor.

open access: yesJournal of Biological Chemistry, 1991
The interleukins comprise a class of hormones that have a definite known secondary and tertiary structure under physiologic conditions. The interleukin-2 is the leader in T cell differentiation. The interleukin-2 acts via interaction with high affinity, cell bound receptors (IL-2R). High affinity IL-2 receptors are constructed by cooperative binding of
P, Marino, A, Preatoni
openaire   +4 more sources

Structure-function relationships for the interleukin 2 receptor system

open access: yesMemorias do Instituto Oswaldo Cruz, 1987
Receptors for interleukin 2 (IL-2) esit in at least three forms which differ in their subunit compositio, their affinity for ligand and their ability to mediate a cellular reponse.
Richard J. Robb
doaj   +1 more source

Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease [PDF]

open access: yes, 2009
Traditionally, Crohn's disease has been associated with a Th1 cytokine profile, while Th2 cytokines are modulators of ulcerative colitis. This concept has been challenged by the description of tolerising regulatory T cells (Treg) and by proinflammatory ...
Brand, Stephan
core   +1 more source

Killer-Cell Inhibitory Receptors, CD158a/b, are Upregulated by Interleukin-2, but not Interferon-γ or Interleukin-4

open access: yesMediators of Inflammation, 1999
Although it is now accepted that killer-cell inhibitory receptors (KIRs), which were molecularly cloned in 1995, deliver negative signals to natural killer (NK) cells regarding the recognition of target cells, it is still unclear how the expression of ...
Toshiaki Kogure   +6 more
doaj   +1 more source

Targeted Activation of T Cells with IL-2-Coupled Nanoparticles

open access: yesCells, 2020
Interleukin-2 (IL-2) is a T cell growth factor particularly required in regulatory T cell maintenance and memory T cell responses. High-dose IL-2 treatment was the first FDA-approved immunotherapy for cancer, while low-dose IL-2 administration has shown ...
Verena K. Raker   +3 more
doaj   +1 more source

Evidence for Monocyte Reprogramming in a Long-Term Postsepsis Study

open access: yesCritical Care Explorations, 2022
OBJECTIVES:. This study sought to identify monocyte alterations from septic patients after hospital discharge by evaluating gene expression of inflammatory mediators and monocyte polarization markers.
Raquel Bragante Gritte, PhD   +15 more
doaj   +1 more source

Suppression of interleukin-1 beta and LDL scavenger receptor expression in macrophages by a selective protein kinase C inhibitor.

open access: yesJournal of Lipid Research, 1991
A human monocytic cell line, THP-1, stimulated with 40 nM phorbol myristate acetate (PMA), differentiated to macrophage-like cells, and exhibited increased expression and release of interleukin-1 beta and expression of acetylated low density lipoprotein (
AL Akeson   +4 more
doaj   +1 more source

The Interleukin 2 Receptor

open access: yesAnnual Review of Cell and Developmental Biology, 1988
Publisher Summary Although it was assumed initially that the various activities found in conditioned media were solely produced by lymphocytes, this idea was broadened subsequently to allow for activities that are produced by nonlymphoid cells, and the term cytokine is now sometimes used.
openaire   +3 more sources

Post-ischaemic immunological response in the brain: targeting microglia in ischaemic stroke therapy [PDF]

open access: yes, 2020
Microglia, the major endogenous immune cells of the central nervous system, mediate critical degenerative and regenerative responses in ischaemic stroke.
Chen, Ruoli   +4 more
core   +3 more sources

Interleukin-2 receptor and ovarian cancer [PDF]

open access: yesBritish Journal of Cancer, 1993
Interleukin-2 receptor (IL-2R) can be detected in serum. We estimated the IL-2R in the serum of 78 women, of whom 30 were diagnosed as having malignant ovarian tumours, five had non ovarian tumours, one had a negative second look laparotomy, 11 had benign ovarian tumours, three had uterine fibroids and 28 were age-matched controls.
Owens, OJ   +5 more
openaire   +3 more sources

Home - About - Disclaimer - Privacy